Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The response of Continuous Erythropoietic Receptor Activator (CERA) with different dose
interval and the survey for influence factors:
We aim to evaluate a better clinical response which can be achieved by different dosing
interval of a fixed dose of CERA. We expect this study can determine the dosing schedule with
better clinical response to CERA and identify the associated factors predicting the
cost-effectiveness of CERA in maintenance hemodialysis (HD) patients in Taiwan.